Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Diagnosis of Lung Cancer
share announcement

Clinical Diagnosis of Lung Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 4712

Special Issue Editors

Dr. Andrea Bille

E-Mail Website
Guest Editor
Department of Thoracic Surgery, Guy’s and St. Thomas’ NHS Trust Foundation, London SE1 9RT, UK
Interests: VATS lung resection (lobectomy, segmentectomy); pancoast tumor and airway reconstruction; robotic surgery (mediastinal and lung tumor); pleurectomy decortication for mesothelioma; tracheal surgery; thymoma early and advanced stage surgery; chest wall resection and reconstruction; robotic surgery
Dr. Savvas Lampridis

E-Mail Website
Guest Editor
1. Department of Cardiothoracic Surgery, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
2. Department of Thoracic Surgery, 424 General Military Hospital, Thessaloniki, Greece
Interests: minimally invasive surgery; robotic surgery; translational cardiovascular medicine; military medicine; health policy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Accurate and timely diagnosis is critical for the effective management of lung cancer, the leading cause of cancer-related mortality worldwide. This Special Issue of the Journal of Clinical Medicine will provide an overview of the latest developments in the clinical diagnosis of lung cancer. We welcome original research and comprehensive reviews that showcase recent advances across the continuum of lung cancer diagnosis—from screening and early detection to molecular testing and biomarker discovery. Key topics to be covered include the implementation of lung cancer screening programs, the comparative effectiveness of different imaging modalities, innovations in endoscopic techniques and minimally invasive staging, the role of liquid biopsies, and the validation of emerging molecular biomarkers.

By highlighting cutting-edge findings across diverse disciplines, this issue aims to promote multidisciplinary collaboration and the adoption of best practices. The goal is to achieve earlier diagnosis, more accurate subtyping, and improved staging. The insights presented may guide clinicians in maximizing diagnostic precision, aiding them in selecting optimal treatment approaches and personalized monitoring strategies. Overall, by facilitating state-of-the-art lung cancer diagnosis, this collection of articles can ultimately help to improve patient outcomes for this deadly disease.

Dr. Andrea Bille
Dr. Savvas Lampridis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • bronchoscopy
  • diagnosis
  • imaging
  • liquid biopsy
  • lung cancer
  • mediastinoscopy
  • minimally invasive surgery
  • pathology
  • screening
  • staging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 889 KiB  
Article
The Importance of Comorbidities at Baseline and 5-Year Follow-Up in a Lung Cancer Biomarker Screening Trial
by Nimue Lilith Romeikat, Frank Sullivan, Fergus Daly and Wenyan Kong
J. Clin. Med. 2025, 14(6), 2116; https://doi.org/10.3390/jcm14062116 - 20 Mar 2025
Viewed by 305
Abstract
Background/Objectives: Despite recent lung cancer screening (LCS) studies proving significant mortality reduction, comorbidities are a prominent issue affecting cost effectiveness, which is holding back national implementation. Incidental findings (IFs) of comorbidities make a significant contribution to delayed diagnoses and raise discussions about [...] Read more.
Background/Objectives: Despite recent lung cancer screening (LCS) studies proving significant mortality reduction, comorbidities are a prominent issue affecting cost effectiveness, which is holding back national implementation. Incidental findings (IFs) of comorbidities make a significant contribution to delayed diagnoses and raise discussions about optimal management plans. This is particularly relevant to national lung cancer screening (NLCS), as the high-risk population qualifying for the screening often have increased likelihood for comorbidities due to their smoking history. Methods: The Early Detection of Cancer of the Lung Scotland (ECLS) (ClinicalTrials.gov identifier NCT01925625) study showcases a targeted approach to NLCS by implementing the blood-based biomarker EarlyCDT-Lung test. Firstly, this paper explored the ECLS dataset for comorbidities present within the screening population at baseline A chi-square analysis was then undertaken to investigate the relationship of cohort allocation and incidence of new comorbidities over the five-year follow-up period. Results: High prevalence conditions were cardiovascular (38.5%), neurological/psychiatric (33.9%), gastrointestinal (29.8%), and respiratory (19.2%). While 20.3% of the total patient cohort showed a newly discovered comorbidity, there was no significant variation in new incidences between the intervention and control cohort. Conclusions: When considering these results alongside the all-cause mortality reduction shown in previous analyses, they indicate that this targeted approach to LCS might help improve the benefit–harm ratio through the introduction of biomarkers. Further refining selection criteria for low-dose CT screening might contribute to minimising the risk of overdiagnosis and overtreatment. Full article
(This article belongs to the Special Issue Clinical Diagnosis of Lung Cancer)
►▼ Show Figures

Figure 1

10 pages, 228 KiB  
Article
The Role of Incentive Spirometry in Enhanced Recovery After Lung Cancer Resection: A Propensity Score-Matched Study
by Monica Casiraghi, Riccardo Orlandi, Luca Bertolaccini, Antonio Mazzella, Lara Girelli, Cristina Diotti, Giovanni Caffarena, Silvia Zanardi, Federica Baggi, Francesco Petrella, Patrick Maisonneuve and Lorenzo Spaggiari
J. Clin. Med. 2025, 14(1), 100; https://doi.org/10.3390/jcm14010100 - 27 Dec 2024
Viewed by 976
Abstract
Background: Postoperative physiotherapy is a cornerstone of Enhanced Recovery After Surgery (ERAS) programs, especially following lung resection. Despite its importance, the literature lacks clear recommendations and guidelines, particularly regarding the role of incentive spirometry (IS). This study aims to determine whether incentive spirometry [...] Read more.
Background: Postoperative physiotherapy is a cornerstone of Enhanced Recovery After Surgery (ERAS) programs, especially following lung resection. Despite its importance, the literature lacks clear recommendations and guidelines, particularly regarding the role of incentive spirometry (IS). This study aims to determine whether incentive spirometry offers additional benefits over early ambulation alone in patients undergoing lung resection for primary lung cancer. Methods: We conducted a retrospective case–control study at the European Institute of Oncology (IEO) involving patients who underwent lung resection from June 2020 to June 2022. Patients were divided into two cohorts: early ambulation alone (control group) and early ambulation with IS (IS group). The primary endpoint was the rate of postoperative pulmonary complications. Secondary endpoints included length of hospital stay and time to chest drain removal. A propensity score-matched analysis was performed based on age, sex, and BMI. Data were compared using Chi-squared and Student’s t-tests as appropriate. Results: A total of 304 patients were included, with 153 in the intervention group and 151 in the control group. After propensity-score matching, 52 patients from each cohort were compared. No significant differences were found between the groups regarding postoperative oxygen requirement, fever, atelectasis, residual pleural space, need for bronchoscopy toilette, and re-hospitalization rate. IS group showed trends toward shorter hospital stays and lower time to chest drain removal, though without reaching statistical significance. Conclusions: IS did not significantly improve postoperative outcomes compared to early ambulation alone in patients undergoing lung resection for primary lung cancer. More extensive, prospective, randomized trials are needed to confirm these findings. Full article
(This article belongs to the Special Issue Clinical Diagnosis of Lung Cancer)
14 pages, 769 KiB  
Article
Adenosquamous Carcinoma of the Lung: Survival, Radiologic Findings, PD-L1, and Driver Mutations
by Oliver Illini, Hannah Fabikan, Eva Fischer, Anna Sophie Lang-Stöberl, Dagmar Krenbek, Christa Jarius, Shokoufa Azarnia-Medan, Stefan Gasser, Maximilian Johannes Hochmair, Christoph Weinlinger, Arschang Valipour and Stefan Watzka
J. Clin. Med. 2024, 13(19), 5711; https://doi.org/10.3390/jcm13195711 - 25 Sep 2024
Viewed by 1654
Abstract
Background: Adenosquamous carcinoma of the lung (ASC) is a rare non-small-cell lung cancer (NSCLC) subtype combining components of squamous cell carcinoma (SCC) and adenocarcinoma (AC). Data on ASC, particularly in Caucasian populations, are limited. Methods: We reviewed clinicopathological and radiological characteristics of ASC [...] Read more.
Background: Adenosquamous carcinoma of the lung (ASC) is a rare non-small-cell lung cancer (NSCLC) subtype combining components of squamous cell carcinoma (SCC) and adenocarcinoma (AC). Data on ASC, particularly in Caucasian populations, are limited. Methods: We reviewed clinicopathological and radiological characteristics of ASC patients diagnosed between 1996 and 2023. Patients were classified into AC-predominant ASC (AC-ASC) and SCC-predominant ASC (SCC-ASC) groups for analysis. Results: Among the 66 patients included, the median overall survival was 41.7 (95% CI, 25.0–54.4), while it was 48.1 (95% CI, 27.3–88.0) in patients treated with curative surgery (n = 44) and 15.3 (95% CI, 6.5–42.6) months for palliative patients (n = 22). The five-year survival rates were 39% and 26%, respectively. Recurrence occurred in 43% of stage I patients and was associated with worse survival (HR 3.303 (95% CI, 1.10–9.89) p = 0.033). AC-ASCs (n = 17) more frequently showed air-bronchogram (p = 0.002) and pleural effusions (p = 0.054) compared to SCC-ASCs (n = 26). SCC-ASCs exhibited more vascular invasion (p = 0.006) and PD-L1 values between 1 and 49% (TPS) (p = 0.032). The subtype did not influence survival. EGFR and ALK alterations were found in 17% and 2% of patients, respectively. Conclusions: Despite early-stage disease, ASC patients had a high recurrence rate, associated with worse survival. Clinicopathologic differences between AC-ASCs and SCC-ASCs did not influence survival. Full article
(This article belongs to the Special Issue Clinical Diagnosis of Lung Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 584 KiB  
Case Report
Long-Term Survivor with Paraneoplastic Cerebellar Ataxia and Small-Cell Lung Cancer
by Konstantinos Tsoukalas, Ioannis Ntanasis-Stathopoulos, Angeliki Andrikopoulou, John S. Tzartos, Meletios A. Dimopoulos and Maria Gavriatopoulou
J. Clin. Med. 2025, 14(2), 364; https://doi.org/10.3390/jcm14020364 - 9 Jan 2025
Viewed by 875
Abstract
Background/Objectives: Paraneoplastic cerebellar degeneration (PCD) is an inflammatory autoimmune process caused by onconeural antibodies directed against cerebellar Purkinje cells. In most cases, prognosis is poor as disease progression leads to pancerebellar dysfunction and permanent neurological damage. Through this case report, we aim to [...] Read more.
Background/Objectives: Paraneoplastic cerebellar degeneration (PCD) is an inflammatory autoimmune process caused by onconeural antibodies directed against cerebellar Purkinje cells. In most cases, prognosis is poor as disease progression leads to pancerebellar dysfunction and permanent neurological damage. Through this case report, we aim to highlight the clinical presentation, diagnostic process, and therapeutic implications associated with PCD secondary to SCLC. Methods: Herein, we present the case of a 57-year-old patient diagnosed with PCD who presented with progressive limb ataxia and impaired mobility. CT scans and EBUS (endobronchial ultrasound) bronchoscopy established the diagnosis of limited-stage small-cell lung cancer (SCLC) of the right lung with marked lymphadenopathy. Results: Anti-CV2/CRMP5 and anti-SOX1 autoantibodies were identified in the serum that confirmed the diagnosis of PCD related to SCLC. A total of six cycles of chemotherapy with carboplatin and etoposide resulted in rapid clinical improvement and complete response of the disease. The patient remains in remission six years after the initial diagnosis with no neurological deficits. Conclusions: The prognosis of PCD greatly depends on early detection and management of the underlying malignancy. Despite the poor prognosis, early diagnosis and prompt initiation of chemotherapy may offer a great survival benefit in these patients. Full article
(This article belongs to the Special Issue Clinical Diagnosis of Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop